Trading

J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says

Summary

Johnson and Johnson is reportedly in discussions to acquire Ollin Biosciences for a valuation reaching up to $3.4 billion. According to media reports, the healthcare giant aims to expand its business through this potential multibillion-dollar transaction.

Source: Read the full story at Stock Market News

Follow Tech & Money Press for daily watchlists and market news

XFacebookInstagramTikTok
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.
About UsContactPrivacy PolicyDisclaimer
Not financial advice. Curated headlines link to their original publishers.